
03/06/2025
Despite bearing 20% of the global disease burden, Africa hosts only 3% of clinical trials. This gap limits access to treatments tailored for African populations. There is an urgent need for increased investment, better regulatory frameworks, and community engagement to strengthen Africa’s clinical research capacity and develop effective healthcare solutions for the continent’s unique challenges
Despite facing 20% of the global disease burden, Africa hosts only 3% of clinical trials. Prof. Mansoor Saleh highlights the need for more trials on the continent to ensure treatments are safe, effective, and relevant for African populations, and calls for greater investment, improved regulations, and community engagement to build Africa’s research capacity and address its unique health challenges.
Read more: https://www.businessdailyafrica.com/bd/opinion-analysis/columnists/why-we-should-promote-clinical-trials-in-africa-s-disease-battle-5066860
Prof Mansoor Saleh, Chair, Department of Haematology-Oncology and Founding Director, Cancer Center, Aga Khan University Medical College, East Africa and Aga Khan University Hospital, Nairobi.